1.
Boumpa
s DT, Austin III HA, Fessler BJ, et al. Systemic
lupus erythematosus: Emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med 1995; 122: 940¬950
2. Karakoç Y, Dilek K, Güllülü M, Yavuz M, Ersoy A,
Akalın
H
, Yurtkuran M. Prevalence of hepatitis C virus antibody in patients with SLE. Ann Rheum Dis 1997; 56: 570-571
3. Churg J, Bernstein J, Glassock RJ. Lupus nephritis, in Renal Disease, Classification and Atlas of Glomerular Diseases, edited by Churg J, Bernstein J, Glasscock R.I,
New York, Igaku-Shoin, 1995, p 151
4. Ter Borg EJ, Horst G, Hummel Ej, Limburg PC, Kallenberg CGM. Predictive values of rises in anti-double-stranded DNA anti-body levels for disease exacerbations in systemic lupus erythematosus: a long term prospective study. Arthritis Rheum 1990; 33: 634¬643
5. Kalunian KC, Panosian-Shakian N, Ebling FM, et at. Idiotypic characteristics of immunoglobulins associated with systemic lupus erythematosus. Arthritis Rheum
1989;32:513-522
6. Koffler D, Agnello V, Thoburn R, Kunkel HG. SLE,
prototype of immune complex nephritis in man. J Exp Med 1971; 134: 169- 179
7. Eilat D. Crossreactions of anti-DNA antibodies and the central dogma of lupus nephritis. Immunol Today 1988; 6: 123-127
8. Dziarski R. Autoimmunity: Policlonal activation or antigen induction. Immunol Today 1988; 9: 340-342
9. Lafer EM, Rauch J, Andrzejewski C Jr, et al. Polyspecific monoclonal lupus autoantibodies reactive with polynucleotides and phospholipids. J Exp Med 1981; 153:897-909
10. Faaber P, Rıjke GPM, Van De Putte LBA, et al.
Crossreactivity of human and murine anti-DNA antibodies with heparan sulphate: the major glycosaminogliycan in glomerular basement membrane.
J Clin Invest 1986; 77: 1824-1830
11. Foster MH, Cizman B, Madaio MP. Biology of disease. Nephritogenic autoantibodies in systemic lupus erythematosus: immunochemical properties, mechanism of immune deposition, and genetic origin.
Lab Invest 1993; 69: 494-507
111
12. Jacob L, Viard JD, Allenet N, et al. A monoclonal anti-duble-stranded DNA autoantibody binds to a 94-kDa cell-surface protein on various cell types via nucleosomes or a DNA-histone complex. Proc Natl Acad Sci USA 1989; 86: 4669-4673
13. Termaat RM, Brinkman K, Van Gompel F, et al. Cross-reactivity of monoclonal anti-DNA antibodies with heparan sulphate is mediated via bound DNA/histone complex. J Autoimmun 1990; 3: 531-545
14. Termaat RM, Assmann KJM, Van Son JPHF, et al.
Antigen-specificity of antibodies bound to glomeruli of mice with systemic lupus erythematosus-like syndromes. Lab Invest 1993; 68: 164-173
15. Chan TM, Frampton G, Staines NA, et al. Different mechanism by which anti-DNA Moabs bind to human endothelial cells and glomerular mesangial cells. Clin
Exp Immunol 1992; 88: 68-74
16. Brinkman K, Termaat RM, Berden JHM, Smeenk RJT.
Anti-DNA antibodies and lupus nephritis: the complexity of crossreactivity. Immunol today 1990; 11:
232-234
17. Kramers C, Hylkema NM, Van Bruggen MCI, et al. Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo. J Clin Invest
1994;94:568-577
18. Diamond B, Katz JB, Paul E, et al. The role of somatic mutation in the pathogenic anti-DNA response. Ann.
Rev Immunol 1992; 10: 731-757
19. Bell DA, Morrison B, Vandenbygarrt P. Immunogenic DNA-related factors. Nucleosomes spontaneously released from normal murine lymhoid cells stimulate proliferation and immunglobulin synthesis of normal
mouse lymhocytes. J Clin Invest 1990; 85: 1487-1496
20. Burlingame RW, Boey ML, Starkebaum G, Rubin RL.
The central role of chromatin in autoimmune responses to histones and DNA in systemic lupus erythematosus. J Clin Invest 1994; 94: 184-192
21. Chabre H, Amoura Z, Piette JC, et al. Presence of nucleosome-restricted antibodies in patients with systemic lupus erythematosus. Arhritis Rheum 1995;
38: 1485-1491
22. Bernstein KA, Di Valerio R, Lefkowith JB. Glomerular binding activity in MRL Ipr serum consist of antibodies that bind to a DNA/histone/type IV collagen complex. J Immunol 1995; 154: 2424-2433
23. Rumore PM, Steinmann CR. Endegenous circulating DNA in systemic lupus erythematosus. Occurence as multimeric complexes bound to histone. J Clin Invest
1990; 86: 69-74
24. Emlen W, Niebur J, Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 1994; 152: 3685-3692
25. Watanabe-Fukunaga R, Brannan CI, Copeland NG, et al. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature
1992:356:314-317
26. Singer GG, Carrera AC, Marshak-Rothstein A, et al. Apoptosis, Fas and systemic autoimmunity: the
MRL/lpr model. Curr Opin Immunol 1994; 6: 913-920
27. Nagata S, Suda T. Fas and Fas ligand: Ipr and gld mutations. Immunol Today 1995; 16: 39-43
28. Strasser A, Whittingham S, Vaux DL, et al. Enforced bcl-2 expression in B-lymphoid cells prolongs antibody responses and exhibits autoimmune diseases. Proc Natl Acad Sci USA 1991; 88: 8661-8665
29. Siegert CEH, Daha MR, Westedt ML, Van Der Voort
EAM, Breedveld FC. IgG autoantibodies against Clq are correlated with nephritis, hypocomplementaemia, and dsDNA antibodies in systemic lupus erythematosus. J Rheumatol 1991; 18: 230-234
30. Siegert CEH, Daha MR, Tseng C, et al. Predictive value of IgG autoantibodies against Clq for nephritis in systemic lupus erythematosus. Ann Rheum Dis
1993;52:851-856
112
Thank you for copying data from http://www.arastirmax.com
